Construction and Characterization of a CTLA-4-Targeted scFv–Melittin Fusion Protein as a Potential Immunosuppressive Agent for Organ Transplant

Basic Science for the Clinician 55

(2012) Leonard H. Sigal   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Current status of immunosuppressive agents for solid organ transplantation in children

(2012) Tracy Coelho et al.   PEDIATRIC TRANSPLANTATION

Bee venom in cancer therapy

(2011) Nada Oršolić   CANCER AND METASTASIS REVIEWS

Cytotoxic T-Lymphocyte-Associated Antigen-4

(2011) A. K. S. Salama et al.   CLINICAL CANCER RESEARCH

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity

(2010) N. Jain et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS

Clinical pharmacy services and solid organ transplantation: a literature review

(2009) G. Stemer et al.   PHARMACY WORLD & SCIENCE